[Gastric MALT lymphoma - from pathogenetic insights to consequent deescalation of therapy]. / Gastrale MALT-Lymphome von pathogenetischen Erkenntnissen zu konsequenter Deeskalation der Therapie.
Z Gastroenterol
; 60(4): 602-612, 2022 Apr.
Article
em De
| MEDLINE
| ID: mdl-34820809
ABSTRACT
Gastric MALT- (mucosa-associated-lymphoid-tissue) lymphoma represents the most frequent gastrointestinal lymphoma. For decades, surgery and later on radiation and chemotherapy were regarded as established therapy. Some 30 years ago, the pathogenetic role of Helicobacter pylori infection for the development of gastric MALT-lymphoma became evident. During the following years, the pathogenetic insights were consequently implemented into clinical medicine. This lead to a radical change of the therapeutic approach to these lymphoma. Nowadays, Helicobacter pylori eradication is the internationally established therapy of first choice. It is followed by lymphoma regression in most cases. The long-term prognosis of patients after exclusive eradication therapy is excellent, even if endoscopic and/or histological residuals persist and a watch-and-wait strategy is favored.The pathogenetic insights und their clinical application implicated a consequent deescalation of therapy of gastric MALT-lymphoma. This review summarizes the single steps of this development and gives a recommendation for the actual management of patients with gastric MALT lymphoma.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Gástricas
/
Helicobacter pylori
/
Infecções por Helicobacter
/
Linfoma de Zona Marginal Tipo Células B
Tipo de estudo:
Diagnostic_studies
/
Guideline
/
Prognostic_studies
Limite:
Humans
Idioma:
De
Ano de publicação:
2022
Tipo de documento:
Article